A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in subjects With Advanced NSCLC With KRAS p.G12C Mutation

  • Robinson, Jodie J. (PI)
  • Gruzd, Anatoliy (CoPI)
  • Quigley, Kevin (PI)
  • Habib, Muhammad A. (CoPI)
  • Pelot, Ronald (CoPI)

Project: Research project

Project Details

Description

This Phase 1/2 research project is being done to test the effects of AMG 510 and to look for any anti-cancer activity of AMG 510 in patients with advanced solid tumours with KRAS p.G12C mutation.

StatusFinished
Effective start/end date1/1/15 → 5/3/21

Funding

  • Social Sciences and Humanities Research Council of Canada: US$112,843.00

ASJC Scopus Subject Areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Medicine(all)
  • Transportation
  • Sociology and Political Science

Access Project